Lupin Limited has informed the Exchange about further update on acquisition of VISUfarma B.V., the Netherlands.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty Midcap 150 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has provided an update on its previously announced acquisition of VISUfarma B.V., Netherlands, through its wholly owned Dutch subsidiary Nanomi B.V. The deal, originally expected to close by February 28, 2026, has been delayed and is now anticipated to be completed in April 2026. The delay is attributed to the pending satisfaction of specific closing conditions. Lupin is acquiring the entire share capital of VISUfarma, which is an ophthalmology-focused company based in the Netherlands. This is the third communication on the matter, following prior intimations on September 29, 2025 and December 30, 2025.
Short-term impact is likely neutral to mildly negative as the deal closure has been pushed back by roughly two months, though the transaction is still progressing. Strategic implications remain intact as the acquisition supports Lupin's expansion into the European ophthalmology segment.